In their hunt for new approvals, biopharma companies spend billions of dollars every year on clinical trials. In recent years, though, real-world studies as sources of practice-informing data––and even as the basis for new indications––have multiplied. but clinical trials remain the gold standard. In a post-pandemic future, will clinical trials ever look the same again? Could real-world data help fill in the gaps? In this session, we will discuss the role real-world evidence now plays in informing clinical guidelines and…

Mark Trusheim spoke at a California Life Sciences Association briefing on January 26. The briefing was well attended, and the audience included California state legislators.